Dissecting the proteome of lipoproteins: New biomarkers for cardiovascular diseases?

Publication date: Available online 5 January 2015 Source:Translational Proteomics Author(s): Anne von Zychlinski , Torsten Kleffmann Proteomics has proven to be a powerful tool for the characterization of lipoproteins and has provided important insights into the biochemistry and pathophysiology of various lipoprotein classes. It has significantly contributed to the way we now see lipoproteins as complex particles not only involved in lipid transport and exchange, but also in processes such as immune response, inflammation and wound healing. Ongoing proteomics research is focussing on the identification of new candidate markers for cardiovascular disease, the leading cause of death worldwide. The ratio between good cholesterol (high density lipoprotein) and bad cholesterol (low density lipoprotein) is routinely used to estimate an individual’s risk for developing premature coronary heart disease. While statin therapy has proven effects in reducing cardiovascular events, other therapies such as resins, fibrates and niacin have failed to substantially reduce cardiovascular risk. Thus new targets and candidate biomarkers for risk assessment and for the development of alternative drugs and treatments of disease are needed. Here we review the recent findings in lipoprotein proteomics with the main emphasis on studies that differentially displayed various states of diseases and on new targeted, high throughput strategies with the capability to translate discovery findings in...
Source: Translational Proteomics - Category: Biomedical Science Source Type: research

Related Links:

Purpose of review Heterozygous familial hypercholesterolemia often went unrecognized in China when population cholesterol levels were low, but rapid economic development has changed the situation. This review will discuss the current position of awareness, diagnosis, and management of familial hypercholesterolemia in Chinese populations. Recent findings The phenotype of familial hypercholesterolemia in China and other Chinese populations has become similar to that in Western countries, although it may still be somewhat less severe. The prevalence in Chinese populations is also similar to that in other countries and it...
Source: Current Opinion in Lipidology - Category: Lipidology Tags: GENETICS AND MOLECULAR BIOLOGY: Edited by Robert A. Hegele Source Type: research
Abstract PCSK9 protein is a key regulator of LDL receptor activity. Gain-of-function mutations in PCSK9 are one of the genetic causes of familial hypercholesterolemia. Conversely, loss-of-function mutations are associated with lower levels of LDL cholesterol and reduced coronary heart disease. Monoclonal antibodies targeting PCSK9 are highly efficacious in lowering LDL-C levels, with a good tolerability and safety profile. Two PCSK9 inhibitors, alirocumab and evolocumab, have demonstrated a cardiovascular benefit in addition to statin therapy in patients with established cardiovascular disease. A recent European c...
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research
Conclusion: Statins seemed to be beneficial for the primary prevention of CHDs but have no effect on CHD death and all-cause mortality. PMID: 30834266 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
CONCLUSION: Secondary prevention efforts among patients with CHD require additional improvement. Moreover, secondary prevention is currently less successful among the rural population than the urban population. PMID: 30874515 [PubMed - in process]
Source: Turk Kardiyoloji Dernegi arsivi - Category: Cardiology Authors: Tags: Turk Kardiyol Dern Ars Source Type: research
CONCLUSION: Several drugs indicated for the treatment of cardiovascular and related diseases are associated with DiC. Atherosclerosis and microcirculatory disturbances seem to play an important pathogenetic role. PMID: 30833802 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
AbstractPurposeThis post-hoc analysis examined whether age modified the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH), using pooled data from four 78-week placebo-controlled phase 3 trials (ODYSSEY FH I, FH II, LONG TERM, and HIGH FH).MethodsData from 1257 patients with HeFH on maximally tolerated statin ± other lipid-lowering therapies were analyzed by an alirocumab dose regimen and by age subgroups (18 to
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
AbstractElevated serum low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD). Many guidelines recommend LDL-C as a primary treatment target, and statins represent the cornerstone of treatment for lipid management. Recently revised guidelines recommend even more intense management of LDL-C, especially in patients at moderate and high risk. However, LDL-C levels in the Chinese population differ from those in Western populations, and the benefits and safety of the maximum allowable dose of statins have yet to be determined. Furthermore, in practice, many patients do not achieve th...
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
Abstract Coronary heart disease (CHD) remain the leading cause of disability and death in industrialized Countries. Among many conditions that contribute to the etiology and progression of CHD, the presence of high LDL-C levels represent the major risk factor. Therefore, the reduction of LDL-C levels play a key role in the management of patients with high or very high cardiovascular risk. Although statins represent the gold standard therapy for the reduction of cholesterol levels, do not allow to achieve target levels of LDL-C in all patients. Indeed, a significant number of patients result statin-intolerants, esp...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Abstract BACKGROUND: Coronary heart disease (CHD) is a leading cause of mortality among women. Systematic evaluation of the quality of care and outcomes in women hospitalized for acute coronary syndrome (ACS), an acute manifestation of CHD, remains lacking in China. METHODS: The Improving Care for Cardiovascular Disease in China (CCC)-ACS project is an ongoing nationwide registry of the American Heart Association and Chinese Society of Cardiology. Using data from the CCC-ACS project, we evaluated sex differences in acute management, medical therapies for secondary prevention, and in-hospital mortality in 82 1...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
In this issue of Metabolism, Ong et al [1] report that fibroblast growth factor 21 (FGF21) levels could predict major cardiovascular (CV) events (MCVE) in statin-treated patients with stable coronary heart disease (CHD) using data from the Treating to New Targets (TNT) trial (n  = 10,001; median follow-up = 4.9 years) [2]; MCVE were defined as a composite of CHD death, cardiac arrest, fatal or non-fatal stroke and non-fatal myocardial infarction (MI). In the Ong et al study [1], 1996 patients with plasma FGF21 concentrations available at baseline were analyzed; 1 835 of them had also FGF21 measurements at the 1-year timepoint.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
More News: Biochemistry | Biomedical Science | Cardiology | Cardiovascular | Cholesterol | Coronary Heart Disease | Heart | Heart Disease | Niacin | Niaspan | Statin Therapy | Study